Author

Emmanuel M. Ewara

Observed names: E Ewara, E. Ewara, E.M. Ewara, Emmanuel Ewara, Emmanuel M Ewara

Observed institutions: Western University, St. Michael's Hospital, University of Ottawa, Ottawa Hospital Research Institute, Janssen Scientific Affairs (United States), Janssen Canada (Canada)

ORCID: 0000-0001-5354-9329

Observed ORCID: 0000-0001-5354-9329

OpenAlex ID: A5009449478

Cost Savings of Expedited Care with Upfront Next-Generation Sequencing Testing versus Single-Gene Testing among Patients with Metastatic Non-Small Cell Lung Cancer Based on Current Canadian Practices

2023 · Brandon S. Sheffield, Kiefer Eaton, et al. · Current Oncology · 41

PDF

The Importance of Considering Differences in Study Design in Network Meta-analysis: An Application Using Anti-Tumor Necrosis Factor Drugs for Ulcerative Colitis

2017 · Chris Cameron, Emmanuel Ewara, et al. · Medical Decision Making · 33

Cost-Effectiveness of First-Line Treatments for Patients with Kras Wild-Type Metastatic Colorectal Cancer

2014 · E.M. Ewara, G.S. Zaric, et al. · Current Oncology · 29

PDF

Impact of adherence to biological agents on health care resource utilization for patients over the age of 65 years with rheumatoid arthritis

2017 · Urja Lathia, Emmanuel Ewara, et al. · Patient Preference and Adherence · 20

PDF

Prevalence, Treatment Patterns, and Outcomes of Individuals with EGFR Positive Metastatic Non-Small Cell Lung Cancer in a Canadian Real-World Setting: A Comparison of Exon 19 Deletion, L858R, and Exon 20 Insertion EGFR Mutation Carriers

2022 · Dylan E. O’Sullivan, Tamer N. Jarada, et al. · Current Oncology · 19

PDF

A Comparison of Different Analysis Methods for Reconstructed Survival Data to Inform Cost‑Effectiveness Analysis

2019 · Sandjar Djalalov, Jaclyn Beca, et al. · PharmacoEconomics · 17

Real-World Outcomes of Patients with Advanced Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer in Canada Using Data Extracted by Large Language Model-Based Artificial Intelligence

2024 · Ruth Moulson, Jennifer Law, et al. · Current Oncology · 7

PDF

Estimating the Burden of Illness of Relapsed Follicular Lymphoma and Marginal Zone Lymphoma in Ontario, Canada

2023 · John Kuruvilla, Emmanuel M. Ewara, et al. · Current Oncology · 6

PDF

Patterns and predictors of long-term retention of inflammatory bowel or rheumatoid disease patients on innovator infliximab: an analysis of a Canadian prescriptions claims database

2018 · Philip A Baer, Guy Aumais, et al. · Patient Preference and Adherence · 6

Real-World Treatment Patterns, Health Outcomes, and Healthcare Resource Use in Advanced Common EGFR-Positive Non-Small Cell Lung Cancer Patients Treated with Osimertinib in Alberta

2024 · Winson Y. Cheung, Chantelle Carbonell, et al. · Current Oncology · 3

Estimating the Associated Burden of Illness and Healthcare Utilization of Newly Diagnosed Patients Aged ≥65 with Mantle Cell Lymphoma (MCL) in Ontario, Canada

2023 · Peter Anglin, Julia Elia-Pacitti, et al. · Current Oncology · 2

PDF

The Iscore Predicts Total Healthcare Costs Early after Hospitalization for an Acute Ischemic Stroke

2015 · Emmanuel M. Ewara, Wanrudee Isaranuwatchai, et al. · International Journal of Stroke · 2

External Validation of the FLIPI Risk Score Measured at Diagnosis and POD24 Among Individuals With Follicular Lymphoma at the Time of Subsequent Relapse

2023 · Devon J. Boyne, Neil Chua, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

MA12.05 Economic Impact of Delaying Care with Single-Gene Testing Versus Next-Generation Sequencing in Non-small Cell Lung Cancer

2022 · B. Sheffield, K. Eaton, et al. · Journal of Thoracic Oncology · 1

The Cost-Effectiveness of Combination Treatment Consisting of Either Cetuximab or Panitumumab plus FOLFIRI versus Treatment with Bevacizumab plus FOLFIRI as First-Line Treatment for KRAS Wild-Type Metastatic Colorectal Cancer Patients in Ontario

2012 · Emmanuel M. Ewara · Scholarship@Western (Western University) · 1

PDF

PP01.10 Real-World Outcomes of Patients with Advanced EGFR-Mutated NSCLC in Canada Using AI-Extracted Data

2024 · Ruth Moulson, Jennifer Law, et al. · Journal of Thoracic Oncology

PDF

External Validation of the FLIPI Risk Score Measured at Initial Diagnosis and POD24 Among Previously Treated Individuals with Progressed Follicular Lymphoma in Alberta, Canada

2022 · Carolyn Owen, Neil Chua, et al. · Blood

51P Testing patterns and outcomes of different EGFR-positive metastatic non-small cell lung cancer (NSCLC) patients in a Canadian real-world setting

2022 · D.J. Boyne, T. Jarada, et al. · Annals of Oncology

Pcn60 Fitting Distributions of Parametric Models Into Non-parametric Kaplan-meier Curve: Application in Excel and Comparison of Different Data Recreation Methods

2019 · S. Djalalov, J. Beca, et al. · Value in Health

Patterns and predictors of long-term retention of inflammatory bowel or rheumatoid disease patients on innovator infliximab: an analysis of a Canadian prescriptions claims database [Erratum]

2018 · Philip A Baer, Guy Aumais, et al. · Patient Preference and Adherence

PDF

SAT0209 A comparative real-world utilization patterns of innovator and biosimilar infliximab in a treatment naÏve and switch population from germany: a prescription claims analysis

2018 · E.M. Ewara, L. Ellis, et al. · Annals of the Rheumatic Diseases

PDF

A214 a Comparison of Real-world Utilization Patterns of Innovator and Biosimilar Infliximab: a Prescription Claims Data Subgroup Analysis of German Gastroenterologists

2018 · E Ewara, V Jairath, et al. · Journal of the Canadian Association of Gastroenterology

A123 Increasing Time on Treatment Is Predictive of Improved Long-term Retention for Stable Remicade® (infliximab) Inflammatory Bowel Disease Patients in Canada

2018 · J Marshall, M Marrache, et al. · Journal of the Canadian Association of Gastroenterology

P383 Increasing treatment time on REMICADE® (infliximab) predicts subsequent long-term retention in stable infliximab inflammatory bowel disease patients in Canada

2017 · J.K. Marshall, A.M. Marrache, et al. · Journal of Crohn s and Colitis

SAT0611 The Impact of Adherence To Biologic Agents on Health Care Resource Utilization for Patients with Rheumatoid Arthritis

2016 · U. Lathia, F. Nantel, et al. · Annals of the Rheumatic Diseases

Works count: 28

Citation count: 188

H-index: 7

I10-index: 6